NASDAQ · IRWD

Ironwood Pharmaceuticals, Inc.

$3.91 +$0.20 (+5.39%) 1D After hours

Key Metrics

$610.72M
Market cap
5.98×
P/E · TTM
$361.51M
Revenue · TTM
$102.18M
Net income
EPS · TTM $0.63
Dividend yield
Free cash flow $112.18M
Beta · 1Y 1.95
EBITDA · TTM $172.53M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 7
    The stock moved -13.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 7
  • Mar 20
    From its Feb 2 high, the share price fell 38%.

    Peak close $4.94 on Feb 2; trough close $3.04 on Mar 20. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -38%
  • Feb 20
    The stock moved -14.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 20

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$610.72M
Enterprise value
Shares outstanding164.6M
52-wk range$0.72 – $5.57
Avg volume · 20D2.4M
Net cash
Book value / share$-1.35
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Ironwood Pharmaceuticals, Inc.
IPO dateFeb 3, 2010
Employees100

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E5.98
P/S1.69
P/FCF5.44
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating 47.4%
Net 28.3%
FCF 31.0%
ROE / ROIC -39.4% · -23.3%

Financial Health

Current ratio1.41
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$95.99M

Cash Flow · TTM

Operating CF $112.21M
Capex −$34.00K
Free cash flow $112.18M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings